206 related articles for article (PubMed ID: 35122181)
1. Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
Awasthee N; Shekher A; Rai V; Verma SS; Mishra S; Dhasmana A; Gupta SC
Apoptosis; 2022 Apr; 27(3-4):261-282. PubMed ID: 35122181
[TBL] [Abstract][Full Text] [Related]
2. Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer.
Mitra S; Biswas P; Bandyopadhyay A; Gadekar VS; Gopalakrishnan AV; Kumar M; Radha ; Nandy S
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2637-2650. PubMed ID: 37955690
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Kumar S; Agnihotri N
Biomed Pharmacother; 2019 Jan; 109():1462-1477. PubMed ID: 30551398
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
5. Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line.
Seber S; Sirin DY; Yetisyigit T; Bilgen T
Niger J Clin Pract; 2020 Mar; 23(3):386-391. PubMed ID: 32134040
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway.
Gu SM; Lee HP; Ham YW; Son DJ; Kim HY; Oh KW; Han SB; Yun J; Hong JT
Neuromolecular Med; 2018 Sep; 20(3):312-327. PubMed ID: 29802525
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.
Ginzburg S; Golovine KV; Makhov PB; Uzzo RG; Kutikov A; Kolenko VM
Prostate; 2014 Feb; 74(2):177-86. PubMed ID: 24151226
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.
Park JA; Na HH; Jin HO; Kim KC
Mol Cells; 2019 Dec; 42(12):884-892. PubMed ID: 31735020
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro.
Han SS; Son DJ; Yun H; Kamberos NL; Janz S
Leuk Res; 2013 Feb; 37(2):146-54. PubMed ID: 23237561
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
12. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Adam A; Torres D; Zhang X; Dobrolecki LE; Wei W; Lewis MT; Dave B; Chang JC; Landis MD; Creighton CJ; Mancini MA; Tweardy DJ
Oncogene; 2015 Mar; 34(11):1341-53. PubMed ID: 24681959
[TBL] [Abstract][Full Text] [Related]
13. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent.
Sun LD; Wang F; Dai F; Wang YH; Lin D; Zhou B
Biochem Pharmacol; 2015 Jun; 95(3):156-69. PubMed ID: 25850000
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine targets NF-κB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer.
Kumar S; Agnihotri N
Mol Cell Biochem; 2021 Apr; 476(4):1765-1781. PubMed ID: 33433833
[TBL] [Abstract][Full Text] [Related]
15. Isodeoxyelephantopin, a Sesquiterpene Lactone Induces ROS Generation, Suppresses NF-κB Activation, Modulates LncRNA Expression and Exhibit Activities Against Breast Cancer.
Verma SS; Rai V; Awasthee N; Dhasmana A; Rajalaksmi DS; Nair MS; Gupta SC
Sci Rep; 2019 Nov; 9(1):17980. PubMed ID: 31784542
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway.
Zheng J; Son DJ; Gu SM; Woo JR; Ham YW; Lee HP; Kim WJ; Jung JK; Hong JT
Sci Rep; 2016 May; 6():26357. PubMed ID: 27198178
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.
Zou P; Xia Y; Ji J; Chen W; Zhang J; Chen X; Rajamanickam V; Chen G; Wang Z; Chen L; Wang Y; Yang S; Liang G
Cancer Lett; 2016 May; 375(1):114-126. PubMed ID: 26963494
[TBL] [Abstract][Full Text] [Related]
18. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells.
Rawat L; Hegde H; Hoti SL; Nayak V
Biomed Pharmacother; 2020 Aug; 128():110243. PubMed ID: 32470748
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway.
Thongsom S; Suginta W; Lee KJ; Choe H; Talabnin C
Apoptosis; 2017 Nov; 22(11):1473-1484. PubMed ID: 28913568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
